The recent deal for Imsidolimab reflects low confidence in the drug's market potential, despite positive phase 3 results. Rosnilimab showed promising trial results but failed to differentiate ...

AnaptysBio (NASDAQ:ANAB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses ...

AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock? SAN ...

The company has out-licensed its Imsidolimab program, a treatment for generalized pustular psoriasis, to Vanda Pharmaceuticals, securing a $10 million upfront payment, an additional $5 million for ...

Beyond its in-house programs, AnaptysBio benefits from lucrative partnerships. The company has out-licensed its Imsidolimab program, a treatment for generalized pustular psoriasis, to Vanda ...

Additionally, the company entered a licensing agreement with Vanda Pharmaceuticals for imsidolimab, receiving $15 million upfront and potential future milestones. AnaptysBio plans to release ...

The company’s pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to ...

Following after Boehringer in the GPP category is AnaptysBio, which has an IL-36 inhibitor called imsidolimab the phase 3 GEMINI-1 study for the disorder, with results due in the fourth quarter of ...